207 related articles for article (PubMed ID: 30214188)
1. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Kiff C; Ruiz S; Varol N; Gibson D; Davies A; Purkayastha D
Int J Chron Obstruct Pulmon Dis; 2018; 13():2707-2720. PubMed ID: 30214188
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.
Samyshkin Y; Kotchie RW; Mörk AC; Briggs AH; Bateman ED
Eur J Health Econ; 2014 Jan; 15(1):69-82. PubMed ID: 23392624
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
6. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].
Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H
Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425
[TBL] [Abstract][Full Text] [Related]
7. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
8. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
9. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
10. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
12. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P
Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
15. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
16. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs.
Jain R; Cai Q; Sun SX; Tan H
Manag Care; 2015 Aug; 24(8):40-8. PubMed ID: 26399141
[TBL] [Abstract][Full Text] [Related]
20. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Martinez FJ; Rabe KF; Calverley PMA; Fabbri LM; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VKT; Siddiqui S; Reisner C; Zetterstrand S; Román J; Purkayastha D; Bagul N; Rennard SI
Am J Respir Crit Care Med; 2018 Nov; 198(10):1268-1278. PubMed ID: 29763572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
